Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY25 results · Jul–Sep 2024
Astec LifeSciences reported revenue from operations of ₹98.55 crore (down 11.1% from Q2 FY24) and net loss of ₹38.55 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.55 | 110.79 | −11.1% | 69.37 | +42.1% |
| Other income | 2.00 | 0.98 | +104.3% | 0.92 | +116.4% |
| Total income | 100.54 | 111.77 | −10.0% | 70.30 | +43.0% |
| Profit before tax | (38.54) | (17.60) | Loss widened | (61.64) | Loss narrowed |
| Net profit for the period | (38.55) | (13.42) | Loss widened | (39.72) | Loss narrowed |
| Attributable to shareholders of the company | (38.56) | (13.43) | Loss widened | (39.72) | Loss narrowed |
| EPS, basic (₹) | (19.66) | (6.85) | Loss widened | (20.26) | Loss narrowed |
| Net margin (%) | -39.1 | -12.1 | -57.2 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.55 | 110.79 | −11.1% | 69.37 | +42.1% |
| Other income | 1.98 | 0.96 | +107.5% | 0.91 | +118.5% |
| Total income | 100.53 | 111.74 | −10.0% | 70.28 | +43.0% |
| Profit before tax | (38.57) | (17.64) | Loss widened | (61.67) | Loss narrowed |
| Net profit for the period | (38.57) | (13.45) | Loss widened | (39.74) | Loss narrowed |
| EPS, basic (₹) | (19.67) | (6.86) | Loss widened | (20.26) | Loss narrowed |
| Net margin (%) | -39.1 | -12.1 | -57.3 |
Consolidated
- Filed with BSE
- 08 Nov 2024, 15:34 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2024, 15:34 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE